Literature DB >> 11745820

Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer.

D Marrelli1, E Pinto, A De Stefano, G de Manzoni, M Farnetani, L Garosi, F Roviello.   

Abstract

BACKGROUND AND OBJECTIVES: Preoperative positivity of serum tumor markers has been reported to be a prognostic factor in several neoplasms. The aim of this longitudinal study was to evaluate the correlation between CEA, CA 19-9, and CA 72-4 preoperative serum levels and the site of recurrence after curative surgery for gastric cancer.
METHODS: One hundred sixty-seven patients resected for primary gastric cancer between January 1988 and June 1996 were considered. All patients were followed-up according to the same protocol, with a mean follow-up time of 45 +/- 39 months (range: 2-130). The correlation between marker positivity and the incidence of recurrence was studied by means of univariate and multivariate analyses.
RESULTS: A tumor recurrence was found in 92 patients (55.1%). For each of the three markers, preoperative positivity was related to a higher incidence of hematogenous recurrences with respect to negative cases; univariate analysis also revealed a higher incidence of locoregional recurrences in CA 72-4-positive cases. At multivariate analysis, preoperative positivity for one or more tumor markers proved to be an independent predictor of hematogenous recurrences (P < 0.005, relative risk [RR] 4.82), in addition to lymph node involvement (P < 0.05, RR 3.82); no correlation between marker positivity and the onset of locoregional or peritoneal recurrences was found.
CONCLUSIONS: Preoperative positivity for CEA, CA 19-9 or CA 72-4 is an independent risk factor for hematogenous recurrences of gastric carcinoma; this aspect should be considered in the option of using adjuvant chemotherapy after surgery for gastric cancer. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745820     DOI: 10.1002/jso.1163

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

Review 1.  Targeting glycans for CAR therapy: The advent of sweet CARs.

Authors:  Zoe Raglow; Mary Kathryn McKenna; Challice L Bonifant; Wenjing Wang; Marina Pasca di Magliano; Johannes Stadlmann; Josef M Penninger; Richard D Cummings; Malcolm K Brenner; David M Markovitz
Journal:  Mol Ther       Date:  2022-07-12       Impact factor: 12.910

Review 2.  Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer.

Authors:  Chikashi Shibata; Toru Nakano; Akihiro Yasumoto; Atsushi Mitamura; Kentaro Sawada; Hitoshi Ogawa; Tomoya Miura; Ichiro Ise; Kazuhiro Takami; Kuniharu Yamamoto; Yu Katayose
Journal:  BMC Surg       Date:  2022-06-03       Impact factor: 2.030

3.  The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.

Authors:  Minkyu Jung; Hei-Cheul Jeung; Sung Sook Lee; Jun Yong Park; Soojung Hong; Soo Hyeon Lee; Sung Hoon Noh; Hyun Cheol Chung; Sun Young Rha
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-23       Impact factor: 4.553

Review 4.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

5.  A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland.

Authors:  Hong He; Guanfu Chen; Liang Zhou; Yanmin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-26       Impact factor: 4.553

Review 6.  Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.

Authors:  Hideaki Shimada; Tamaki Noie; Manabu Ohashi; Koji Oba; Yutaka Takahashi
Journal:  Gastric Cancer       Date:  2013-04-10       Impact factor: 7.370

Review 7.  Aberrant glycosylation as biomarker for cancer: focus on CD43.

Authors:  Franca Maria Tuccillo; Annamaria de Laurentiis; Camillo Palmieri; Giuseppe Fiume; Patrizia Bonelli; Antonella Borrelli; Pierfrancesco Tassone; Iris Scala; Franco Maria Buonaguro; Ileana Quinto; Giuseppe Scala
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

8.  The value of postoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the early detection of gastric cancer recurrence after curative resection.

Authors:  Eung-Chang Lee; Jun-Young Yang; Kyung-Goo Lee; Seung-Young Oh; Yun-Suhk Suh; Seong-Ho Kong; Han-Kwang Yang; Hyuk-Joon Lee
Journal:  J Gastric Cancer       Date:  2014-12-26       Impact factor: 3.720

Review 9.  Insights into Bioinformatic Applications for Glycosylation: Instigating an Awakening towards Applying Glycoinformatic Resources for Cancer Diagnosis and Therapy.

Authors:  Manikandan Muthu; Sechul Chun; Judy Gopal; Vimala Anthonydhason; Steve W Haga; Anna Jacintha Prameela Devadoss; Jae-Wook Oh
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

10.  A novel prognosis marker based on combined preoperative carcinoembryonic antigen and systemic inflammatory response for resectable gastric cancer.

Authors:  Yubin Ma; Junpeng Lin; Jianxian Lin; Junfang Hou; Qin Xiao; Fang Yu; Zhijun Ma; Ping Li; Ruhong Tu; Jianwei Xie; Chaohui Zheng; Su Yan; Changming Huang
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.